In particular, liraglutide, a novel DM drug with a GLP-1 agonist action, is currently undergoing a clinical trial, i.e., the ELAD trial (Evaluating Liraglutide in Alzheimer’s Disease NCT01843075), and is being investigated for its benefits on changes in AD biomarkers and clinical measures in addition to age and APOE4 status (Femminella et al., 2020). This evidence concerns the gene GCG and early-onset autosomal dominant Alzheimer disease.